Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID -2.55%73 Pretax Margin % is 20.82% as of Mar. 2026, which is 7% below its 10-year median of 22.49. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Pharma Aids ranks better than 85.8% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Pharma Aids's Pre-Tax Income for the
three
months ended in Mar. 2026 was BDT25.7 Mil. Pharma Aids's Revenue for the
three
months ended in Mar. 2026 was BDT123.3 Mil. Therefore, Pharma Aids's pretax margin for the quarter that ended in Mar. 2026 was 20.82%.
The historical rank and industry rank for Pharma Aids's Pretax Margin % or its related term are showing as below:
DHA:PHARMAID'
s Pretax Margin % Range Over the Past 10 Years
Min: 3.34 Med: 22.49 Max: 26.67
Current: 20.53
DHA:PHARMAID's Pretax Margin % is ranked better than 85.8% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.61
vs DHA:PHARMAID: 20.53
Pharma Aids (DHA:PHARMAID) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Pharma Aids Pretax Margin % Related Terms
Pharma Aids Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Pharma Aids's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Pharma Aids's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids (DHA:PHARMAID) has a Pretax Margin % of 20.82% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Pharma Aids and its competitors. This is near median its historical median of 22.49. Over the past decade, Pharma Aids' Pretax Margin % has ranged from 3.34 to 26.67. According to the industry distribution chart, Pharma Aids ranks #116 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 14.2%.
Is Pharma Aids' Pretax Margin % too high?
Pharma Aids' current Pretax Margin % of 20.82% is near median its 10-year median of 22.49. Over the past 10 years, this metric has ranged from a low of 3.34 to a high of 26.67. The Medical Devices & Instruments industry median Pretax Margin % is 2.61. Pharma Aids' value of 20.82% is 697.7% above this industry median. Based on the distribution chart, Pharma Aids ranks #116 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Pretax Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #116 out of 817 companies for Pretax Margin %. This places Pharma Aids in the top 14% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 2.61. Pharma Aids' value of 20.82% is 697.7% above this benchmark. Historically, Pharma Aids' own Pretax Margin % has ranged from 3.34 to 26.67 over the past decade. While the company's 10-year median is 22.49 vs. the industry median of 2.61, Pharma Aids has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.61, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current Pretax Margin % of 20.82% is 697.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Pharma Aids and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current Pretax Margin % is 20.82%, which is near median its own 10-year median of 22.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current Pretax Margin % is 20.82%, which is near median its 10-year median of 22.49 and 697.7% above the Medical Devices & Instruments industry median of 2.61. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Pretax Margin % is 20.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
Pretax Margin %: 20.82% (near median its 10-year median of 22.49)
GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
Industry Position: 697.7% above the Medical Devices & Instruments median (#116 of 817)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
